Organogenesis Holdings (FRA:2PQ) Cyclically Adjusted Revenue per Share: €4.22 (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2PQ Organogenesis Holdings Inc FRA:2PQ
69 GF Score
Price €2.24
GF Value €2.60
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Organogenesis Holdings Cyclically Adjusted Revenue per Share?

Organogenesis Holdings FRA:2PQ -3.45% 69 Cyclically Adjusted Revenue per Share is €4.22 as of Mar. 2026. GuruFocus rates FRA:2PQ with a GF Score™ of 69/100 and a GF Value™ of €2.60 (Modestly Undervalued). The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Organogenesis Holdings's adjusted revenue per share for the three months ended in Mar. 2026 was €0.245. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €4.22 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

As of today (2026-07-20), Organogenesis Holdings's current stock price is €2.24. Organogenesis Holdings's Cyclically Adjusted Revenue per Share for the quarter that ended in Mar. 2026 was €4.22. Organogenesis Holdings's Cyclically Adjusted PS Ratio of today is 0.53.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Organogenesis Holdings was 1.25. The lowest was 0.46. And the median was 0.71.


Organogenesis Holdings  (FRA:2PQ) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Organogenesis Holdings's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=2.24/4.22
=0.53

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PS Ratio of Organogenesis Holdings was 1.25. The lowest was 0.46. And the median was 0.71.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Organogenesis Holdings Cyclically Adjusted Revenue per Share Related Terms


Organogenesis Holdings Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Organogenesis Holdings's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Organogenesis Holdings Cyclically Adjusted Revenue per Share Chart

Organogenesis Holdings Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 4.14

Organogenesis Holdings Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 4.12 4.14 4.22

FRA:2PQ vs TKNO, AKBA, SIGA: Cyclically Adjusted Revenue per Share Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Organogenesis Holdings's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Organogenesis Holdings Cyclically Adjusted PS Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Organogenesis Holdings's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Organogenesis Holdings's Cyclically Adjusted PS Ratio falls into.


FRA:2PQ
69GF Score
Organogenesis Holdings Inc FRA:2PQ
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Organogenesis Holdings Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Organogenesis Holdings's adjusted Revenue per Share data for the three months ended in Mar. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.245/330.2130*330.2130
=0.245

Current CPI (Mar. 2026) = 330.2130.

Organogenesis Holdings Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201606 0.000 241.018 0.000
201609 0.000 241.428 0.000
201612 3.394 241.432 4.642
201703 0.000 243.801 0.000
201706 0.000 244.955 0.000
201709 0.000 246.819 0.000
201712 4.329 246.524 5.799
201803 0.448 249.554 0.593
201806 0.562 251.989 0.736
201809 0.626 252.439 0.819
201812 0.726 251.233 0.954
201903 0.558 254.202 0.725
201906 0.634 256.143 0.817
201909 0.632 256.759 0.813
201912 0.687 256.974 0.883
202003 0.535 258.115 0.684
202006 0.585 257.797 0.749
202009 0.789 260.280 1.001
202012 0.669 260.474 0.848
202103 0.646 264.877 0.805
202106 0.763 271.696 0.927
202109 0.722 274.310 0.869
202112 0.849 278.802 1.006
202203 0.685 287.504 0.787
202206 0.866 296.311 0.965
202209 0.893 296.808 0.994
202212 0.827 296.797 0.920
202303 0.767 301.836 0.839
202306 0.814 305.109 0.881
202309 0.762 307.789 0.818
202312 0.689 306.746 0.742
202403 0.767 312.332 0.811
202406 0.913 314.175 0.960
202409 0.775 315.301 0.812
202412 0.933 315.605 0.976
202503 0.635 319.799 0.656
202506 0.689 322.561 0.705
202509 0.980 324.800 0.996
202512 1.364 324.054 1.390
202603 0.245 330.213 0.245

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €4.22 mean?
Organogenesis Holdings (FRA:2PQ) has a Cyclically Adjusted Revenue per Share of €4.22 as of Mar. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Organogenesis Holdings and its competitors.
Is Organogenesis Holdings' Cyclically Adjusted Revenue per Share too high?
Organogenesis Holdings' current Cyclically Adjusted Revenue per Share is €4.22. Overall, Organogenesis Holdings has a GF Score™ of 69/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Organogenesis Holdings' Cyclically Adjusted Revenue per Share compare to TKNO and AKBA?
Organogenesis Holdings' Cyclically Adjusted Revenue per Share of €4.22 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Drug Manufacturers company?
A good Cyclically Adjusted Revenue per Share depends on the Drug Manufacturers industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Organogenesis Holdings and its competitors. Organogenesis Holdings's current Cyclically Adjusted Revenue per Share is €4.22. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Organogenesis Holdings stock overvalued right now?
Based on GuruFocus' analysis, Organogenesis Holdings (FRA:2PQ) is currently considered Modestly Undervalued. The stock's GF Value™ is €2.60, compared to a current price of €2.24 — trading 13.8% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €4.22. Organogenesis Holdings' overall GF Score™ is 69/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Organogenesis Holdings (FRA:2PQ), the current Cyclically Adjusted Revenue per Share is €4.22 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Organogenesis Holdings (FRA:2PQ) Overvalued in 2026?

Based on GuruFocus' analysis, Organogenesis Holdings stock appears to be undervalued. The current stock price of €2.24 is trading 13.8% below its estimated GF Value™ of €2.60. GuruFocus considers Organogenesis Holdings to be Modestly Undervalued.

Key valuation signals for FRA:2PQ:

  • Cyclically Adjusted Revenue per Share: €4.22
  • GF Value™: €2.60 vs. price of €2.24 (13.8% below fair value)
  • GF Score™: 69/100 with 5 warning signs

No single metric tells the full story. See the FRA:2PQ stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Organogenesis Holdings Business Description

Other Exchanges ORGO:USA
Address 85 Dan Road, Canton, MA, USA, 02021
Organogenesis Holdings Inc is a regenerative medicine company focused on the development, manufacture, and commercialization of product solutions for the advanced wound care, surgical, and sports medicine markets. The company's portfolio of regenerative medicine products in the advanced wound care category includes Apligraf, Dermagraft, PuraPly AM, CYGNUS Dual, etc., and the sports medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM, and PuraPly SX for management of open wounds in the surgical setting. The company operates in a single segment, that is, regenerative medicine.
69GF Score

Get the complete analysis for FRA:2PQ

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.24
Price
€2.60
GF Value